News & Updates

Show Multimedia Only

First-line cabozantinib-atezolizumab boosts PFS in advanced HCC

06 Jan 2022 by

The combination of cabozantinib and atezolizumab in the first-line setting significantly improved progression-free survival (PFS) compared with sorafenib in patients with advanced hepatocellular carcinoma (HCC), according to results of the phase III COSMIC-312 trial presented at ESMO Asia 2021.

First-line cabozantinib-atezolizumab boosts PFS in advanced HCC

06 Jan 2022

Age does not affect survival after liver transplant

04 Jan 2022

While older recipients of living donor liver transplantation (LDLT) appear to suffer from worse mortality outcomes, such deficiency may be attributable to clinical confounders, a recent study has found. In controlled analysis, older and younger patients show comparable long-term survival following LDLT.

Age does not affect survival after liver transplant

04 Jan 2022

Delayed tacrolimus dose reduction plus basiliximab yields better kidney function after liver transplant

04 Jan 2022

A delayed dose reduction of tacrolimus, along with induction of basiliximab, helps suppress kidney injury in liver transplant recipients, as opposed to standard-dose tacrolimus, a recent study has found. Such benefits come with no excess risk of rejection, graft loss, or death.

Delayed tacrolimus dose reduction plus basiliximab yields better kidney function after liver transplant

04 Jan 2022

Chronic air pollution exposure ups MAFLD risk

01 Jan 2022

Prolonged exposure to ambient air levels of particulate matter ≤1 µm (PM1), ≤2.5 µm (PM2.5), and ≤10 µm (PM10), as well as of nitrogen dioxide (NO2), appears to aggravate the likelihood of metabolic dysfunction-associated fatty liver disease (MAFLD), a recent study has found.

Chronic air pollution exposure ups MAFLD risk

01 Jan 2022

Indices of liver fibrosis tied to diabetic peripheral neuropathy in type 2 diabetes

30 Dec 2021

In people with type 2 diabetes, liver fibrosis, measured according to indices, may be associated with diabetic peripheral neuropathy (DPN), a recent study has found.

Indices of liver fibrosis tied to diabetic peripheral neuropathy in type 2 diabetes

30 Dec 2021

Urinary L-FABP predicts 3-month mortality, complications in decompensated cirrhosis

25 Dec 2021

In patients with decompensated cirrhosis, high urinary levels of the liver fatty acid-binding protein (L-FABP) appear to predict the risk of mortality and of acute-on-chronic liver failure, a recent study has found.

Urinary L-FABP predicts 3-month mortality, complications in decompensated cirrhosis

25 Dec 2021

Drinking water may reduce NAFLD prevalence in men

22 Dec 2021

Higher intake of plain water appears to suppress newly diagnosed nonalcoholic fatty liver disease (NAFLD) among men but not women, a recent study has found.

Drinking water may reduce NAFLD prevalence in men

22 Dec 2021

New algorithm predicts HCC risk in compensated advanced chronic liver disease

19 Dec 2021

A novel algorithm using post-treatment age, albumin, and liver stiffness measurement (LSM), among other parameters, can accurately stratify patients with compensated advanced chronic liver disease (cACLD) according to their de novo hepatocellular carcinoma (HCC) risk, a new study shows.

New algorithm predicts HCC risk in compensated advanced chronic liver disease

19 Dec 2021

NAFLD prevalent in IBD patients

16 Dec 2021 by

The incidence of nonalcoholic fatty liver disease (NAFLD) is high among individuals with inflammatory bowel disease (IBD), according to data presented at AIBD 2021.

NAFLD prevalent in IBD patients

16 Dec 2021

Study offers clues on which patients may safely stop HBV therapy

15 Dec 2021 by

Think twice before withdrawing HBV treatment. Not all patients can safely discontinue nucleos(t)ide analogue (NA) therapy as shown in the retrospective RETRACT-B study of patients from Europe, North America, and Asia.

Study offers clues on which patients may safely stop HBV therapy

15 Dec 2021

News & Updates

Showing Hepatology articles

Showing

Specialty:

First-line cabozantinib-atezolizumab boosts PFS in advanced HCC

First-line cabozantinib-atezolizumab boosts PFS in advanced HCC

Age does not affect survival after liver transplant

Age does not affect survival after liver transplant

Delayed tacrolimus dose reduction plus basiliximab yields better kidney function after liver transplant

Delayed tacrolimus dose reduction plus basiliximab yields better kidney function after liver transplant

Chronic air pollution exposure ups MAFLD risk

Chronic air pollution exposure ups MAFLD risk

Indices of liver fibrosis tied to diabetic peripheral neuropathy in type 2 diabetes

Indices of liver fibrosis tied to diabetic peripheral neuropathy in type 2 diabetes

Urinary L-FABP predicts 3-month mortality, complications in decompensated cirrhosis

Urinary L-FABP predicts 3-month mortality, complications in decompensated cirrhosis

Drinking water may reduce NAFLD prevalence in men

Drinking water may reduce NAFLD prevalence in men

New algorithm predicts HCC risk in compensated advanced chronic liver disease

New algorithm predicts HCC risk in compensated advanced chronic liver disease

NAFLD prevalent in IBD patients

NAFLD prevalent in IBD patients

Study offers clues on which patients may safely stop HBV therapy

Study offers clues on which patients may safely stop HBV therapy